Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07123454 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
A Phase 1 study of B-Cell Non-Hodgkin Lymphoma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
- 20
- Study locations
NCT07123454: Recruiting Phase 1 study of B-Cell Non-Hodgkin Lymphoma, sponsored by AstraZeneca.
NCT07123454 is a Phase 1 study of B-Cell Non-Hodgkin Lymphoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 91 participants, below the 126-participant average among 24 other B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07123454, a Phase 1 study of B-Cell Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL).
Primary Outcome
To identify the maximum tolerated dose (MTD) and/or doses of AZD4512 for subsequent evaluation in participants with R/R B-NHL
Conditions Studied
Interventions
- DRUG AZD4512
Study Locations (20)
Other
- Research Site - Melbourne
- Research Site - Chengdu
- Research Site - Guangzhou
- Research Site - Bologna
- Research Site - Milan
- Research Site - Milan
- Research Site - Bunkyō City
- Research Site - Kōtoku
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Taichung
- Research Site - Taipei
- Research Site - London
New York
- Research Site - New York
- Research Site - New York
California
- Research Site - Irvine
Florida
- Research Site - Jacksonville
Minnesota
- Research Site - Rochester
Ohio
- Research Site - Cleveland
Tennessee
- Research Site - Franklin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2025-09-24 |
| Est. Completion | 2028-03-01 |
| Phase | Phase 1 |
What NCT07123454 shows while recruiting
NCT07123454 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 126-participant average among 24 other B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (28% lower).
The record links to 1 condition, with B-Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which AZD4512 is the first listed.
NCT07123454 names 20 study sites across 7 states, led by Other, New York, California.
Frequently Asked Questions
What is clinical trial NCT07123454 about?
NCT07123454 is a clinical study titled "A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma". This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL).
What is the current status of trial NCT07123454?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2025-09-24. Estimated completion is 2028-03-01.
What conditions does trial NCT07123454 study?
This clinical trial studies the following conditions: B-Cell Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT07123454?
The interventions under investigation include: AZD4512 (DRUG).
Who is sponsoring clinical trial NCT07123454?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07123454 being conducted?
This trial has 20 study locations across California, Florida, Minnesota, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-Cell Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07123454's enrollment target sits among peer trials
91 11th of 24 higher than 14 of 24 other B-Cell Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other B-Cell Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RECRUITING · Phase 1
-
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
RECRUITING · Phase 1
-
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
RECRUITING · Phase 1
-
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI